Scholar Rock Reports $105.5 Million Net Loss in Q1 2026, Increases Cash Reserves to $430.5 Million

Scholar Rock Holding Corporation reported its financial results for the first quarter of 2026, revealing a net loss of $105.5 million, compared to a net loss of $74.7 million for the same period in 2025. The company's total operating expenses increased to $102.0 million from $77.1 million year-over-year, driven primarily by a significant rise in general and administrative expenses, which surged by 76.7% to $50.2 million. Research and development expenses also rose by 6.4% to $51.8 million, reflecting ongoing investments in clinical trials and product development.

The company's cash and cash equivalents increased to $430.5 million as of March 31, 2026, up from $323.5 million at the end of 2025. This increase was attributed to proceeds from an at-the-market (ATM) offering, where Scholar Rock sold 2.6 million shares, generating net proceeds of $111.8 million. Additionally, the company secured $196.7 million from a new debt facility, which was used to pay off previous obligations. The total cash, cash equivalents, and marketable securities reached $479.9 million, providing a solid liquidity position to support ongoing operations.

In terms of operational developments, Scholar Rock continues to advance its lead product candidate, apitegromab, which is in development for spinal muscular atrophy (SMA). The company resubmitted its Biologics License Application (BLA) to the FDA in March 2026, with a Prescription Drug User Fee Act (PDUFA) action date set for September 30, 2026. The company is also exploring additional indications for apitegromab and has ongoing trials, including a Phase 2 study for patients with facioscapulohumeral muscular dystrophy (FSHD) expected to initiate in mid-2026.

Scholar Rock's employee headcount has increased as part of its strategy to build infrastructure in anticipation of potential product launches. The company reported a significant rise in employee-related costs, which contributed to the increase in general and administrative expenses. As of March 31, 2026, the company had 119.1 million shares outstanding, reflecting the issuance of new shares through its ATM program and the exercise of pre-funded warrants.

Looking ahead, Scholar Rock anticipates continued significant operating losses as it invests in the development of its product candidates and prepares for commercialization efforts. The company expects to incur substantial expenses related to the ongoing clinical trials for apitegromab and other programs, while also seeking additional partnerships to support its pipeline. The management believes that the existing cash and marketable securities will be sufficient to fund operations into 2027, although additional capital will be necessary for the completion of clinical development and commercialization efforts.